PAVM
PAVmed Inc.NASDAQHealthcare$9.85-3.81%ClosedMarket Cap: $5.3M
As of 2026-04-06
Valuation
P/E (TTM)
13.19
PEG
—
P/B
0.23
P/S
75.94
EV/EBITDA
-2.69
DCF Value
$-17,617.16
FCF Yield
-118498.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-291.5%
Operating Margin
-30715.5%
Net Margin
564.8%
ROE
1.0%
ROA
1.0%
ROIC
-61.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $52.0K | -98.1% | $-6.8M | $-1.3M | $-2.37 | — |
| FY 2025 | $71.0K | -354.9% | $-21.8M | $-3.77B | $-5.63 | — |
| Q3 2025 | $5.0K | -1000.0% | $-4.8M | $-5.4M | $-8.70 | — |
| Q2 2025 | $6.0K | -583.3% | $-4.7M | $-11.9M | $-22.20 | — |
| Q1 2025 | $8.0K | -887.5% | $-5.4M | $19.0M | $10.11 | — |
| Q4 2024 | $10.0K | -380.0% | $-5.2M | $1.4M | $3.61 | — |
| FY 2024 | $3.0M | -101.6% | $-44.5M | $39.8M | $14.88 | — |
| Q3 2024 | $996.0K | -38.7% | $-11.6M | $64.4M | $43.22 | — |
| Q2 2024 | $979.0K | -101.3% | $-13.7M | $-10.8M | $-35.75 | — |
| Q1 2024 | $1.0M | -72.7% | $-14.0M | $-15.2M | $-78.62 | — |
| Q4 2023 | $1.0M | -53.6% | $-16.4M | $-14.0M | $-58.07 | — |
| FY 2023 | $2.5M | -161.8% | $-68.8M | $-64.2M | $-274.92 | — |